Get started
Author

Nicholas Fry

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children
2020 · Azmi Nasser, Tesfaye Liranso, et al. · Clinical Therapeutics · 87
PDF
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
2022 · Azmi Nasser, Joseph T. Hull, et al. · CNS Drugs · 57
PDF
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
2021 · Azmi Nasser, Tesfaye Liranso, et al. · Clinical Therapeutics · 56
A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder
2021 · Azmi Nasser, Tesfaye Liranso, et al. · Journal of Clinical Psychopharmacology · 47
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.
2021 · Azmi Nasser, Tesfaye Liranso, et al. · PubMed Central · 36
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Lisdexamfetamine in Healthy Adults
2021 · Shamia L. Faison, Nicholas Fry, et al. · Journal of Clinical Psychopharmacology · 29
Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults
2020 · Shamia L. Faison, Nicholas Fry, et al. · Clinical Drug Investigation · 24
PDF
An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder
2024 · Ann Childress, Andrew J. Cutler, et al. · CNS Drugs · 6
PDF
Application of the Impulsive Aggression Diary in Adolescents with Attention-Deficit/Hyperactivity Disorder
2019 · Gianpiera Ceresoli-Borroni, Tesfaye Liranso, et al. · Journal of Child and Adolescent Psychopharmacology · 3
Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension Trial
2025 · Robert L. Findling, Alain Katic, et al. · CNS Drugs · 2
PDF
Qelbree (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults with ADHD
2024 · Ann Childress, Andrew Cutler, et al. · CNS Spectrums · 2
PDF
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
2022 · Azmi Nasser, Joseph T. Hull, et al. · CNS Drugs · 2
PDF
2.43 Viloxazine Extended-Release Capsules in Children and Adolescents With ADHD: Final Results of a Long-Term, Phase 3, Open-Label Extension Study
2023 · Robert L. Findling, James G. Waxmonsky, et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 1
PDF
Routine Central Venous Catheter Maintenance After Pediatric Hematopoietic Stem Cell Transplant: Direct Cost Observations From a Single Center and Practice Variation Across Engraft Centers
2026 · Steffani Maier, Christopher E. Dandoy, et al. · Pediatric Transplantation
Correction: An Open‑Label Extension Study Assessing the Long‑Term Safety and Efficacy of Viloxazine Extended‑Release Capsules in Adults with Attention‑Deficit/Hyperactivity Disorder
2026 · Ann Childress, Andrew J. Cutler, et al. · CNS Drugs
PDF
Viloxazine Extended-Release Capsules in Children and Adolescents with ADHD: Final Results of a Long-Term, Phase 3, Open-Label Extension Study
2024 · Robert L. Findling, Nicholas Fry, et al. · CNS Spectrums
PDF
Works count: 17
Citation count: 356
H-index: 7
I10-index: 7
Year
Topic
Type